Primaquine at alternative dosing schedules for preventing relapse in people with Plasmodium vivax malaria
References
Additional references
Arévalo‐Herrera M, Lopez‐Perez M, Medina L, Moreno A, Gutierrez JB, Herrera S. Clinical profile of Plasmodium falciparum and Plasmodium vivax infections in low and unstable malaria transmission settings of Colombia. Malaria Journal 2015;14:154.
Ashley EA, Recht J, White NJ. Primaquine: the risks and the benefits. Malaria Journal 2014;13:418.
Baird JK, Rieckmann KH. Can primaquine therapy for vivax malaria be improved?. Trends in Parasitology 2003;19(3):115‐20.
Baird JK, Hoffman SL. Primaquine therapy for malaria. Clinical Infectious Diseases 2004;39(9):1336‐45.
Baird JK. Evidence and implications of mortality associated with acute Plasmodium vivax malaria. Clinical Microbiology Reviews 2013;26(1):36–57.
Baird JK. Origins and implications of neglect of G6PD deficiency and primaquine toxicity in Plasmodium vivax malaria. Pathogens and Global Health 2015;109(3):93‐106.
Baird JK. Point‐of‐care G6PD diagnostics for Plasmodium vivax malaria is a clinical and public health urgency. BMC Medicine 2015;13:296.
Bassat Q, Velarde M, Mueller I, Lin J, Leslie T, Wongsrichanalai C, et al. Key knowledge gaps for Plasmodium vivax control and elimination. American Journal of Tropical Medicine and Hygiene 2016;95(6 Suppl):62‐71.
Battle KE, Karhunen MS, Bhatt S, Gething PW, Howes RE, Golding N, et al. Geographical variation in Plasmodium vivax relapse. Malaria Journal 2014;13:144.
Bennett JW, Pybus BS, Yadava A, Tosh D, Sousa JC, McCarthy WF, et al. Primaquine failure and cytochrome P‐450 2D6 in Plasmodium vivax malaria. New England Journal of Medicine 2013;369(14):1381‐2.
Betuela IN, Robinson LJ, Hetzel MW, Laman MO, Siba PM, Bassat QU, et al. Primaquine treatment for Plasmodium vivax – an essential tool for malaria control and elimination in Papua New Guinea. Papua and New Guinea Medical Journal 2014;57((1‐4)):68‐74.
Bhattacharjee P, Dubey S, Gupta VK, Agarwal P, Mahato MP. The clinicopathologic manifestations of Plasmodium vivax malaria in children: a growing menace. Journal of Clinical and Diagnostic Research 2013;7(5):861‐67.
Brutus L, Santalla J, Schneider D, Avila JC, Deloron P. Plasmodium vivax malaria during pregnancy, Bolivia. Emerging Infectious Diseases 2013;19(10):1605‐11.
Cheng Q, Cunningham J, Gatton ML. Systematic review of sub‐microscopic P. vivax infections: prevalence and determining factors. PLoS Neglected Tropical Diseases 2015;9(1):e3413.
Cibulskis R. Plasmodium vivax: a roadblock on the quest to eliminate malaria. Lancet Infectious Diseases 2015;15(10):1127‐8.
Clyde DF, McCarthy VC. Radical cure of Chesson strain vivax malaria in man by 7, not 14, days of treatment with primaquine. American Journal of Tropical Medicine and Hygiene 1977;26(3):562‐3.
Douglas NM, Pontororing GJ, Lampah DA, Yeo TW, Kenangalem E, Poespoprodjo JR, et al. Mortality attributable to Plasmodium vivax malaria: a clinical audit from Papua, Indonesia. BMC Medicine 2014;12:217.
Galappaththy GNL, Tharyan P, Kirubakaran R. Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine. Cochrane Database of Systematic Reviews 2013, Issue 10. [DOI: 10.1002/14651858.CD004389.pub3]
Gething PW, Elyazar IR, Moyes CL, Smith DL, Battle KE, Guerra CA, et al. A long neglected world malaria map: Plasmodium vivax endemicity in 2010. PLoS Neglected Tropical Diseases 2012;6(9):e1814.
Gogtay N, Kannan S, Thatte UM, Olliaro PL, Sinclair D. Artemisinin‐based combination therapy for treating uncomplicated Plasmodium vivax malaria. Cochrane Database of Systematic Reviews 2013, Issue 10. [DOI: 10.1002/14651858.CD008492.pub3]
GRADE Working Group, McMaster University. GRADEpro GDT. Version accessed 19 April 2017. Hamilton (ON): GRADE Working Group, McMaster University, 2014.
Grietens KP, Soto V, Erhart A, Ribera JM, Toomer E, Tenorio A, et al. Adherence to 7‐day primaquine treatment for the radical cure of P. vivax in the Peruvian Amazon. American Journal of Tropical Medicine and Hygiene 2010;82(6):1017‐23.
Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. The Cochrane Collaboration. Available from www. cochrane‐handbook.org.
Howes RE, Piel FB, Patil AP, Nyangiri OA, Gething PW, Dewi M, et al. G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model‐based map. PLoS Medicine 2012;9(11):e1001339.
John GK, Douglas NM, von Seidlein L, Nosten F, Baird JK, White NJ, et al. Primaquine radical cure of Plasmodium vivax: a critical review of the literature. Malaria Journal 2012;11:280.
Kochar DK, Das A, Kochar A, Middha S, Acharya J, Tanwar GS, et al. A prospective study on adult patients of severe malaria caused by Plasmodium falciparum, Plasmodium vivax and mixed infection from Bikaner, northwest India. Journal of Vector Borne Diseases 2014;51(3):200‐10.
Koepfli C, Rodrigues PT, Antao T, Orjuela‐Sánchez P, Van den Eede P, Gamboa D, et al. Plasmodium vivax diversity and population structure across four continents. PLoS Neglected Tropical Diseases 2015;9(6):e0003872.
Kumar A, Valecha N, Jain T, Dash AP. Burden of malaria in India: retrospective and prospective view. American Journal of Tropical Medicine and Hygiene 2007;77(6 Suppl):69‐78.
Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. The Cochrane Collaboration.
Llanos‐Cuentas A, Lacerda MV, Rueangweerayut R, Krudsood S, Gupta SK, Kochar SK, et al. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double‐blind, randomised, phase 2b dose‐selection study. Lancet 2014;383(9922):1049‐58.
Looareesuwan S, Buchachart K, Wilairatana P, Chalermrut K, Rattanapong Y, Amradee S, et al. Primaquine‐tolerant vivax malaria in Thailand. Annals of Tropical Medicine and Hygiene 1997;91(8):939–43.
McGready R, Lee S, Wiladphaingern J, Ashley E, Rijken M, Boel M, et al. Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population‐based study. Lancet Infectious Diseases 2012;12(5):388‐96.
Mendis K, Sina BJ, Marchesini P, Carter R. The neglected burden of Plasmodium vivax malaria. American Journal of Tropical Medicine and Hygiene 2001;64(1‐2 Suppl):97‐106.
Mikolajczak SA, Vaughan AM, Kangwanrangsan N, Roobsoong W, Fishbaugher M, Yimamnuaychok N, et al. Plasmodium vivax liver stage development and hypnozoite persistence in human liver‐chimeric mice. Cell Host & Microbe 2015;17(4):526‐35.
Reddy D (Medicines for Malaria Venture). End of Year Review 2016. www.mmv.org/sites/default/files/uploads/docs/news/2016_end_of_year_review.pdf 22 December 2016 (accessed 19 April 2017).
Mueller I, Galinski MR, Baird JK, Carlton JM, Kochar DK, Alonso PL, et al. Key gaps in the knowledge of Plasmodiumvivax, a neglected human malaria parasite. Lancet Infectious Diseases 2009;9(9):555‐66.
Murphy GS, Basri H, Purnomo, Andersen EM, Bangs MJ, Mount DL, et al. Vivax malaria resistant to treatment and prophylaxis with chloroquine. Lancet 1993;341(8837):96‐100.
Newby G, Bennett A, Larson E, Cotter C, Shretta R, Phillips AA, et al. The path to eradication: a progress report on the malaria‐eliminating countries. Lancet 2016;387(10029):1775‐84.
Nkhoma ET, Poole C, Vannappagari V, Hall SA, Beutler E. The global prevalence of glucose‐6‐phosphate dehydrogenase deficiency: a systematic review and meta‐analysis. Blood Cells, Molecules, and Diseases 2009;42(3):267‐78.
Rajapakse S, Rodrigo C, Fernando SD. Tafenoquine for preventing relapse in people with Plasmodium vivax malaria. Cochrane Database of Systematic Reviews 2015, Issue 4. [DOI: 10.1002/14651858.CD010458.pub2]
Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Rijken MJ, McGready R, Boel ME, Poespoprodjo R, Singh N, Syafruddin D, et al. Malaria in pregnancy in the Asia‐Pacific region. Lancet Infectious Diseases 2012;12(1):75–88.
Rizvi I, Tripathi DK, Chughtai AM, Beg M, Zaman S, Zaidi N. Complications associated with Plasmodium vivax malaria: a retrospective study from a tertiary care hospital based in western Uttar Pradesh, India. Annals of African Medicine 2013;12(3):155‐9.
Robinson LJ, Wampfler R, Betuela I, Karl S, White MT, Li Wai Suen CS, et al. Strategies for understanding and reducing the Plasmodium vivax and Plasmodium ovale hypnozoite reservoir in Papua New Guinean children: a randomised placebo‐controlled trial and mathematical model. PLoS Medicine 2015;12(10):e1001891.
Saint‐Yves IFM. Comparison of treatment schedules for Plasmodiumvivax infections in the Solomon Islands. Papua and New Guinea Medical Journal 1977;20(2):62–5.
Schmidt LH, Fradkin R, Vaughan D, Rasco J. Radical cure of infections with Plasmodium cynomolgi: a function of total 8‐aminoquinoline dose. American Journal of Tropical Medicine and Hygiene 1977;26(6 Pt 1):1116‐28.
Singh J, Purohit B, Desai A, Savardekar L, Shanbag P, Kshirsagar N. Clinical manifestations, treatment, and outcome of hospitalized patients with Plasmodium vivax malaria in two Indian States: a retrospective study. Malaria Research and Treatment 2013;2013:341862.
Sutanto I, Tjahjono B, Basri H, Taylor WR, Putri FA, Meilia RA, et al. Randomized, open‐label trial of primaquine against vivax malaria relapse in Indonesia. Antimicrobial Agents and Chemotherapy 2013;57(3):1128‐35.
Takeuchi R, Lawpoolsri S, Imwong M, Kobayashi J, Kaewkungwal J, Pukrittayakamee S, et al. Directly‐observed therapy (DOT) for the radical14‐day primaquine treatment of Plasmodium vivax malaria on the Thai‐Myanmar border. Malaria Journal 2010;9:308.
Vale N, Moreira R, Gomes P. Primaquine revisited six decades after its discovery. European Journal of Medicinal Chemistry 2009;44(3):937‐53.
White NJ. Determinants of relapse periodicity in Plasmodium vivax malaria. Malaria Journal 2011;10:297.
White MT, Shirreff G, Karl S, Ghani AC, Mueller I. Variation in relapse frequency and the transmission potential of Plasmodium vivax malaria. Proceedings. Biological Sciences 2016;283(1827):20160048.
World Health Organization. Methods for surveillance of antimalarial drug efficacy. http://www.who.int/iris/handle/10665/44048(accessed October 2016).
World Health Organization. Control and elimination of Plasmodium vivax malaria. A technical brief. http://apps.who.int/iris/bitstream/10665/181162/1/9789241509244_eng.pdf?ua=1&ua=1(accessed October 2016).
World Health Organization. Guidelines for the Treatment of Malaria. 3rd Edition. Geneva: World Health Organization, 2015.
World Health Organization. Eliminating malaria. http://apps.who.int/iris/bitstream/10665/205565/1/WHO_HTM_GMP_2016.3_eng.pdf(accessed October 2016).
World Health Organization. World Malaria Report 2016. http://apps.who.int/iris/bitstream/10665/252038/1/9789241511711‐eng.pdf?ua=1(accessed April 2017).
Figures and Tables -
Figure 1
Logic framework: treatment outcome pathways in Plasmodium vivax liver hypnozoite infection
| Objective | Intervention | Control |
| Are higher doses more effective (0.5 mg/kg or 30 mg primaquine/day for 14 days), in all areas, or only in areas where they are standard treatment (Asia, Pacific)? | Blood‐stage antimalarial drug with primaquine 0.5 mg/kg (30 mg) per day for 14 days (total dose 420 mg) Both intervention and control groups must have received the same treatment: either CQ or ACT for the blood‐borne stage of infection. | Blood‐stage antimalarial drug with primaquine 0.25 mg/kg (15 mg) per day for 14 days (total dose 210 mg) Both intervention and control groups must have received the same treatment: either CQ or ACT for the blood‐borne stage of infection. |
| Are shorter, higher dose regimes of primaquine over 7 days as effective as treatment over 14 days (is the total dose rather than the length of treatment the important factor)? | Blood‐stage antimalarial drug with primaquine 0.5 mg/kg (30 mg) per day for 7 days (total dose 210 mg) Both intervention and control groups must have received the same treatment: either CQ or ACT for the blood‐borne stage of infection. | |
| Are weekly dosing regimens (0.75 mg/kg or 45 mg/week for 8 weeks) as effective? | Blood‐stage antimalarial drug with primaquine 0.75/kg (45 mg) per week for 8 weeks (total dose 360 mg) | |
| CQ = Chloroquine ACT = Artemisinin‐based combination therapy | ||
Figures and Tables -
Table 1. Data extraction: Grouping of comparisons to address the review objectives
